P2Y2受体激动剂治疗干眼的研究进展

干眼是一类累及眼表和泪膜的多因素疾病.临床上治疗干眼的传统方法主要是被动性增加泪液,如人工泪液点眼、泪小点栓塞等,但新的关于干眼发病机制的研究表明,理想的干眼治疗方法是促进泪腺分泌泪液.研究已经证实,P2Y2受体激动剂具有促进水分及黏蛋白分泌的作用,可以促进泪腺主动分泌泪液.目前研制了多种人工合成的P2Y2受体激动剂并用于干眼的治疗,临床研究证实,P2Y2受体激动剂能够明显增加水性泪液的分泌和黏蛋白的分泌,改善临床症状,且Ⅰ期临床试验证实其具有较好的安全性.就近年来P2Y2受体激动剂在干眼治疗方面的作用机制、临床疗效和研究进展进行综述.

Recent advance in P2Y2 receptor agonist for the treatment of dry eye

Dry eye is a group of multifactor-induced ocular surface symptoms.The conventional therapy for dry eye is to increase the tear passively,such as topical administration of artificial tears eye drops and blockage of lacrimal punctum.However,with a better understanding of pathogenesis of dry eye,it is thought that an ideal method for dry eye is to promote the secretion of tear.Studies showed that P2Y2 receptor agonists can promote the lacrimal gland to secrete tear actively.Up to now,multiple synthetic P2Y2 receptor agonist mimics have been studied,and these studies confirmed that these drugs can improve the secretion of not only water-like tear but also mucoprotein,which can alleviate symptoms in patients with dry eye.In addition,good safety also is clarified by clinical trial of phase Ⅰ.This review briefly summarize the researches on active mechanism,clinical efficacy and applying prospect of P2Y2 receptor agonist for the treatment of dry eye.